Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Mistelbach – page 38

889 clinical trials in Mistelbach, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mistelbach at a glance
889
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

889 trials in Mistelbach

Open in trial search

Study on the Effectiveness and Safety of CHF6001 DPI with Roflumilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Roflumilast
  • Sponsor:Chiesi Farmaceutici S.p.A.

Dermatitis atopic

Not recruiting

Study on the Long-Term Safety and Efficacy of Nemolizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

Crohn's disease

Not recruiting

Study on the Effects of Etrasimod Arginine for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Etrasimod Arginine
  • Sponsor:Arena Pharmaceuticals Inc.

Neurodermatitis

Not recruiting

Study on the Long-Term Safety and Effectiveness of Nemolizumab for Patients with Prurigo Nodularis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

Colitis ulcerative+1

Not recruiting

Study on the Long-Term Effects of TEV-48574 (Duvakitug) for Adults with Moderate to Severe Ulcerative Colitis or Crohn's Disease

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Systemic scleroderma

Not recruiting

Study on the Effects of Fipaxalparant in Patients with Diffuse Cutaneous Systemic Sclerosis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fipaxalparant
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Ovarian cancer

Not recruiting

Study on the Effectiveness of Durvalumab, Olaparib, and Bevacizumab in Patients with Newly Diagnosed Advanced Ovarian Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Astrazeneca AB

Study on BHV-7000 for Patients with Generalized Tonic-clonic Seizures in Idiopathic Generalized Epilepsy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Study on the Effectiveness and Safety of Polatuzumab Vedotin, Rituximab, and CHP in Patients with Untreated Diffuse Large B-Cell Lymphoma

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Polatuzumab Vedotin
  • Sponsor:F. Hoffmann-La Roche AG

Cardiac amyloidosis

Not recruiting

Study of Vutrisiran for Patients with Transthyretin Amyloidosis and Heart Disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Vutrisiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study on the Effects of Semaglutide in Patients with Early Alzheimer's Disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Study on the Effects of Zibotentan and Dapagliflozin in Patients with Chronic Kidney Disease and High Protein Levels

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Astrazeneca AB

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Mistelbach

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking studies focusing on stroke prevention and management of atrial fibrillation. Research evaluates innovative treatments comparing asundexian to established medications for reducing stroke risk in patients with irregular heartbeat.

  • Stroke Prevention
  • Atrial Fibrillation Management
  • Systemic Embolism Prevention

Trials aim to assess both effectiveness and safety profiles of new therapeutic approaches.

02 Oncology Studies

Advanced research in breast cancer treatment, specifically focusing on hormone receptor-positive/HER2-negative early breast cancer. Studies evaluate the effectiveness of combining palbociclib with standard endocrine therapy.

  • Early Breast Cancer Treatment
  • Endocrine Therapy Enhancement
  • Disease-Free Survival Assessment

Research aims to improve treatment outcomes through innovative combination therapies.

03 Neurology Research

Innovative studies examining treatments for acute ischemic stroke and high-risk transient ischemic attacks. Research evaluates the efficacy of milvexian in reducing stroke risk compared to placebo.

  • Acute Stroke Treatment
  • Ischemic Attack Prevention
  • Neurological Recovery

Focus on developing more effective interventions for stroke prevention and management.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.